Psoriasis

18 trials 5 recruiting MedDRA PT
18 Registered trials
5 Recruiting
12 Unique sponsors
14 Unique IMPs
15 Commercial trials
Drug classes (ATC)
— ATC code not specified 14
L Oncology (ATC L) 3
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
JAK inhibitor 3 substances
Monoclonal antibody (humanized) 1 substance
Monoclonal antibody (human) 1 substance
Monoclonal antibody 1 substance
Phase III: 7 Phase II: 6 Phase IV: 1 Phase I: 1 Phase I (Other): 2 Other: 1

Filter these 18 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 18 trials

Phase III

7 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    RISANKIZUMAB
    2022-500408-22-00 3 countries 2022 n=70
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    RISANKIZUMAB; USTEKINUMAB
    2023-504156-10-00 3 countries 2021 n=72
    Ended
  • Alumis Inc. Commercial
    APREMILAST; ENVUDEUCITINIB
    2023-507193-40-00 6 countries 2025 n=681
    Ended
  • Alumis Inc. Commercial
    APREMILAST; ENVUDEUCITINIB
    2023-508959-39-00 9 countries 2025 n=608
    Ended
  • Alumis Inc. Commercial
    ENVUDEUCITINIB
    2024-511166-36-00 13 countries 2025 n=931
    Recruiting
  • Janssen - Cilag International Commercial
    GUSELKUMAB
    2023-508424-34-00 1 country 2019 n=828
    Ended
  • Takeda Development Center Americas Inc. Commercial
    ZASOCITINIB
    2025-522567-15-00 4 countries 2026 n=54
    Recruiting

Phase II

6 trials
  • DICE Therapeutics Inc. Commercial
    DC-806
    2022-502249-90-00 5 countries 2023 n=206
    Ended
  • DICE Therapeutics Inc. Commercial
    LY4100511
    2024-512207-39-00 4 countries 2025 n=134
    Ended
  • Idorsia Pharmaceuticals Ltd. Commercial
    IDOR-1117-2520C
    2025-523051-64-00 2 countries 2026 n=18
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    SAR441566
    2023-503911-14-00 7 countries 2024 n=242
    Ended
  • Amsterdam UMC Stichting Academic
    SODIUM FLUORIDE (18F)
    2024-514759-13-01 1 country 2024 n=15
    Recruiting
  • Arctic Therapeutics ehf. Academic
    PEHERO
    2022-501850-12-00 4 countries 2023 n=376
    Ended

Phase IV

1 trial
  • Charite Universitaetsmedizin Berlin KöR Academic
    DEUCRAVACITINIB
    2023-508948-22-00 1 country n=30
    Ended

Phase I

1 trial
  • Coultreon Biopharma Commercial
    IMP not specified
    2025-522571-28-00 1 country 2025 n=88
    Recruiting

Phase I (Other)

2 trials
  • DICE Therapeutics Inc. Commercial
    DC-806; DC-806, [14C] DC-806
    2023-505367-36-00 1 country 2023 n=8
    Ended
  • Janssen - Cilag International Commercial
    IMP not specified
    2025-523430-14-00 1 country 2025 n=18
    Ended

Other

1 trial
  • Fresenius Kabi SwissBioSim GmbH Commercial
    IMP not specified
    2025-522422-13-00 1 country 2025 n=160
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
DICE Therapeutics Inc. Commercial 3 Phase I (Other), Phase II 0
Alumis Inc. Commercial 3 Phase III 1
Janssen - Cilag International Commercial 2 Phase I (Other), Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 2 Phase III 1
Coultreon Biopharma Commercial 1 Phase I 1
Fresenius Kabi SwissBioSim GmbH Commercial 1 Other 0
Idorsia Pharmaceuticals Ltd. Commercial 1 Phase II 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 0
Takeda Development Center Americas Inc. Commercial 1 Phase III 1
Amsterdam UMC Stichting Academic 1 Phase II 1
Arctic Therapeutics ehf. Academic 1 Phase II 0
Charite Universitaetsmedizin Berlin KöR Academic 1 Phase IV 0
New trials by year
2019
1
2021
1
2022
1
2023
3
2024
2
2025
7
2026
2
← All indication landscapes